Purity
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its binding ability in a functional ELISA. Immobilized human LDL at 5 µg/mL (100 µL/well) can bind Recombinant Human LIMPII/SR-B2 Fc Chimera with a linear range of
0.078-5 µg/mL.Source
Mouse myeloma cell line, NS0-derived
Human LIMPII
(Arg27-Thr432)
Accession # Q14108IEGRMD Human IgG1
(Pro100-Lys330)N-terminus C-terminus Accession #
N-terminal Sequence
AnalysisArg27
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
73 kDa (monomer)
SDS-PAGE
105-115 kDa, reducing conditions
1966-LM |
| |
Formulation Lyophilized from a 0.2 μm filtered solution in Tris-Citrate and NaCl. | ||
Reconstitution Reconstitute at 200 μg/mL in sterile PBS. | ||
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. | ||
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: LIMPII/SR-B2
LIMPII (Lysosomal Integral Membrane Protein II), also known as LPG85 (85 kDa lysosomal membrane sialoglycoprotein) and as CD36 antigen-like 2 (CD36L2), is a major lysosomal membrane protein. It belongs to the scavenger receptor class B subfamily and is designated member 2 (SR-B2). Other mammalian members of this family include SR-B1 (alternatively known as Cla-1 and CD36L1), and SR-B3 (CD36) (1-3). SR-B/CD36 family members are type III integral membrane proteins with an N- as well as a C-terminal cytoplasmic tail, and a large extracellular (or lumenal in the case of LIMPII) loop containing similarly spaced cysteine residues and multiple glycosylation sites. The C-terminal cytoplasmic tail has a di-leucine-based motif that mediates effective lysosomal targeting. LIMPII is widely expressed on all tissues and cell types so far examined. It is also expressed on the surface of activated platelets. LIMPII binds thrombospondin-1, but the biological significance of this interaction is not known. LIMPII-thrombospondin interaction may contribute to the pro-adhesive changes of activated platelets during coagulation, and inflammation (1). Overexpression of LIMPII causes an enlargement of early endosomes and late endosomes, suggesting that LIMPII may play a role in lysosome/endosome biogenesis (4). Mice deficient in LIMPII are impaired in membrane transport processes, resulting in ureteric pelvic junction obstruction, deafness and peripheral neuropathy (5).
References:
Crombie, R. and R. Silverstein (1998) J. Biol. Chem. 273:4855.
Febbraio, M. et al. (2001) J. Clin. Invest. 108:785.
Eskelinen, E-L. et al. (2003) Trends in Cell Biology 13:137.
Kuronita, T. et al. (2002) J. Cell Sci. 115:4117.
Gamp, A-C. et al. (2003) Human Molecular Genetics 12:631.
Long Name:
Lysosomal Integral Membrane Protein II
Entrez Gene IDs:
950 (Human); 12492 (Mouse)
Alternate Names:
AMRF; CD36 antigen (collagen type I receptor, thrombospondin receptor)-like 2(lysosomal integral membrane protein II); CD36 antigen; CD36L2; CD36L2LIMP II; HLGP85; LGP85; LIMP-2,85 kDa lysosomal sialoglycoprotein scavenger receptor class B, member 2; LIMPII; LIMPIICD36 antigen-like 2; LPG85; lysosome membrane protein 2; Lysosome membrane protein II; SCARB2; Scavenger receptor class B member 2,85 kDa lysosomal membrane sialoglycoprotein; scavenger receptor class B, member 2; SRB2; SR-B2; SR-BII
